Basmisanil
- Generic Name
- Basmisanil
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20FN3O5S
- CAS Number
- 1159600-41-5
- Unique Ingredient Identifier
- 788PET5SUA
- Background
Basmisanil has been used in trials studying the treatment and basic science of Down Syndrome.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 7
- Registration Number
- NCT05307679
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2021-02-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 214
- Registration Number
- NCT02953639
- Locations
- 🇺🇸
Booker, J. Gary, MD, APMC, Shreveport, Louisiana, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States
A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke
- First Posted Date
- 2016-10-10
- Last Posted Date
- 2019-01-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 5
- Registration Number
- NCT02928393
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇫🇷CHU de Besancon Hopital Jean Minjoz; Service de Neurologie, Besançon, France
🇫🇷Hopital Gabriel Montpied CHU de Clermont-Ferrand; Service de Neurologie B, Clermont-Ferrand, France
Basmisanil Positron Emission Tomography Study in Japanese Volunteers
- First Posted Date
- 2015-08-27
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT02534207
- Locations
- 🇬🇧
Hammersmith Medicines Research; Central Middlesex Hospital, London, United Kingdom
🇬🇧Imanova Limited, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.